Advertisement
Advertisement
CUVL
Clinuvel Pharmaceuticals Limited - ADR
5.79
USDSponsored
-0.01
-0.17%
Sep 23, 15:54 UTC -4
Closed
After-Market
5.79
0.00
-0.09%
CUVL Earnings Reports
Positive Surprise Ratio
CUVL beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Clinuvel Pharmaceuticals Limited - ADR earnings per share and revenue
On Aug 27, 2026, CUVL reported earnings of 0.46 USD per share (EPS) for Q4 26, missing the estimate of 0.50 USD, resulting in a -8.79% surprise. Revenue reached 57.09 million, compared to an expected 61.24 million, with a -6.77% difference. The market reacted with a -11.44% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Clinuvel Pharmaceuticals Limited - ADR's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Clinuvel Pharmaceuticals Limited - ADR reported EPS of $0.46, missing estimates by -8.79%, and revenue of $57.09M, -6.77% below expectations.
How did the market react to Clinuvel Pharmaceuticals Limited - ADR's Q4 2026 earnings?
The stock price moved down -11.44%, changed from $7.64 before the earnings release to $6.77 the day after.
When is Clinuvel Pharmaceuticals Limited - ADR expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Clinuvel Pharmaceuticals Limited - ADR's next earnings report?
Based on --
analysts, Clinuvel Pharmaceuticals Limited - ADR is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.